Nexavar

The company's marketing partner, Mylan Inc., has received a tentative approval for its abbreviated new drug application (ANDA) for Sorafenib Tablets, 200mg, with the USFDA.

Bayer to challenge India's patent office order on Nexavar

Bayer AG has said it will approach the high court in Mumbai against a ruling by Intellectual Property Appellate Board that upheld the compulsory licence issued to India's Natco Pharma to make and sell a low-cost generic of the German drug major's patented cancer drug Nexavar.

Natco Pharma soars 12% on Nexavar case win

Shares of Natco Pharma rallied as much as 11.7 percent in early trade on Tuesday as the company won Nexavar case against Bayer.

India rules against Bayer in cancer drug patent case

An Indian patent appeals board dismissed on Monday Bayer AG's petition against a government decision to allow a domestic company to sell cheap copycat versions of cancer drug Nexavar, delivering a blow to global drugmakers' monopolies on high-priced medicines.

Drug groups eye Indian legal case

Chennai may be a long way from the Leverkusen headquarters of Bayer BAY, but the German pharmaceutical group is involved in a legal dispute in the southern Indian city that is being watched by its peers around the world.

Bayer fights courts for Nexavar as cheaper rivals take over

German drugmaker Bayer may be fighting it out in the courtroom to defend its patent rights on cancer drug Nexavar. But out in the market, it's already lost considerable market share to cheaper variants from Cipla and Natco.

Developing world supports India's compulsory licence policy

CNBC-TV18's Archana Shukla reports that India's grant of a compulsory licence to Natco for Bayer's kidney-cancer drug Nexavar has sent shockwaves across the globe

Experts divided over compulsory drug licence dispute

By granting compulsory license to Natco for Bayer's kidney cancer drug Nexavar, the Indian government has opened a legal can of worms, reports CNBC-TV18's Archana Shukla.

Cancer drug wars! Cipla slashes prices

It's a drug war, but with a difference and it's been kicked off by Cipla. CNBC TV18's Archana Shukla reports that country's second largest drug firm has slashed prices of three of its key cancer drugs by more than half, making cancer medication costs come down by over 50%.

Cipla gets US FDA tentative nod; stock gains

Cipla has got US FDA tentative nod for HIV-1 drug Viramune generic, reports Business Standard.

Chasing cheaper cancer drugs

In a nondescript suburb south of London, tucked away behind a big hospital, Paul Workman and fellow scientists are celebrating victory in the "World Cup" of cancer drug research for their work in discovering a stream of new medicines.

Natco wins compulsory license from Bayer for cancer drug

In a landmark judgement by India's Patent Office, Natco Pharma has won a compulsory license from Bayer for patent protected anti-cancer drug Nexavar, chemically known as Sorafenib.